Allan Weber

2.3k total citations
46 papers, 1.7k citations indexed

About

Allan Weber is a scholar working on Pharmacology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Allan Weber has authored 46 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pharmacology, 15 papers in Pulmonary and Respiratory Medicine and 13 papers in Epidemiology. Recurrent topics in Allan Weber's work include Antibiotics Pharmacokinetics and Efficacy (15 papers), Cystic Fibrosis Research Advances (13 papers) and Pneumonia and Respiratory Infections (11 papers). Allan Weber is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (15 papers), Cystic Fibrosis Research Advances (13 papers) and Pneumonia and Respiratory Infections (11 papers). Allan Weber collaborates with scholars based in United States, Germany and Gambia. Allan Weber's co-authors include Arnold L. Smith, Bonnie W. Ramsey, Judy Williams‐Warren, Robin L. Davis, Jeffrey R. Koup, Jack Lévy, Paul M. Mendelman, Gregory J. Redding, Edmond J. Gore and K E Opheim and has published in prestigious journals such as American Journal of Clinical Nutrition, Clinical Infectious Diseases and CHEST Journal.

In The Last Decade

Allan Weber

46 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Allan Weber United States 23 740 467 361 257 234 46 1.7k
Paul O. Madsen United States 33 1.4k 1.9× 673 1.4× 795 2.2× 248 1.0× 252 1.1× 196 3.8k
P Periti Italy 21 231 0.3× 450 1.0× 505 1.4× 283 1.1× 175 0.7× 107 1.9k
Paul M. Beringer United States 22 348 0.5× 500 1.1× 362 1.0× 175 0.7× 286 1.2× 64 1.4k
Olivier Petitjean France 22 213 0.3× 667 1.4× 450 1.2× 225 0.9× 330 1.4× 89 1.6k
Stuart M. Harding United States 23 558 0.8× 500 1.1× 277 0.8× 83 0.3× 358 1.5× 40 1.7k
F. Sörgel Germany 29 230 0.3× 1.3k 2.7× 646 1.8× 303 1.2× 571 2.4× 99 2.6k
Joost Wauters Belgium 27 459 0.6× 309 0.7× 913 2.5× 215 0.8× 68 0.3× 117 2.4k
F. P. V. Maesen Netherlands 21 717 1.0× 465 1.0× 507 1.4× 143 0.6× 270 1.2× 83 1.5k
Nicolas Grégoire France 24 317 0.4× 808 1.7× 551 1.5× 160 0.6× 875 3.7× 73 1.7k
C Grassi Italy 22 486 0.7× 181 0.4× 501 1.4× 138 0.5× 106 0.5× 85 1.5k

Countries citing papers authored by Allan Weber

Since Specialization
Citations

This map shows the geographic impact of Allan Weber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan Weber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan Weber more than expected).

Fields of papers citing papers by Allan Weber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allan Weber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan Weber. The network helps show where Allan Weber may publish in the future.

Co-authorship network of co-authors of Allan Weber

This figure shows the co-authorship network connecting the top 25 collaborators of Allan Weber. A scholar is included among the top collaborators of Allan Weber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan Weber. Allan Weber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weber, Allan, Jinsong Ni, Andrew Acheampong, et al.. (2004). Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. Journal of Lipid Research. 45(4). 757–763. 101 indexed citations
2.
Woodward, D.F., et al.. (2004). Bimatoprost: A Novel Antiglaucoma Agent. Cardiovascular Drug Reviews. 22(2). 103–120. 43 indexed citations
3.
Graff, Gavin R., et al.. (2003). Montelukast pharmacokinetics in cystic fibrosis. The Journal of Pediatrics. 142(1). 53–56. 15 indexed citations
4.
Cohn, Leah A., et al.. (2001). Pseudomonas aeruginosaInfection of Respiratory Epithelium in a Cystic Fibrosis Xenograft Model. The Journal of Infectious Diseases. 183(6). 919–927. 15 indexed citations
5.
Weber, Allan, et al.. (2001). CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit. Biopharmaceutics & Drug Disposition. 22(4). 157–168. 17 indexed citations
6.
Weber, Martin W., Salvacion Gatchalian, Arnold L. Smith, et al.. (1999). Chloramphenicol pharmacokinetics in infants less than three months of age in the Philippines and The Gambia. The Pediatric Infectious Disease Journal. 18(10). 896–901. 6 indexed citations
7.
Weber, Allan, et al.. (1997). Effect of nebulizer type and antibiotic concentration on device performance. Pediatric Pulmonology. 23(4). 249–260. 79 indexed citations
8.
Weber, Allan, et al.. (1997). Effect of nebulizer type and antibiotic concentration on device performance. Pediatric Pulmonology. 23(4). 249–260. 5 indexed citations
9.
Anker, John N. van den, Rik C. Schoemaker, Wim C.J. Hop, et al.. (1995). Ceftazidime pharmacokinetics in preterm infants: Effects of renal function and gestational age*. Clinical Pharmacology & Therapeutics. 58(6). 650–659. 51 indexed citations
10.
Weber, Allan, Judy Williams‐Warren, Bonnie W. Ramsey, & Arnold L. Smith. (1995). TOBRAMYCIN SERUM CONCENTRATIONS AFTER AEROSOL AND ORAL ADMINISTRATION IN CYSTIC FIBROSIS. American Journal of Therapeutics. 2(2). 81–87. 15 indexed citations
11.
Weber, Allan, et al.. (1995). Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrobial Agents and Chemotherapy. 39(1). 34–39. 102 indexed citations
12.
Weber, Allan, Arnold L. Smith, Judy Williams‐Warren, Bonnie W. Ramsey, & David S. Covert. (1994). Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatric Pulmonology. 17(5). 331–339. 23 indexed citations
13.
Groot, Ronald de, et al.. (1990). Pharmacokinetics of ticarcillin in patients with cystic fibrosis: A controlled prospective study. Clinical Pharmacology & Therapeutics. 47(1). 73–78. 34 indexed citations
14.
Sherry, Bettylou, et al.. (1989). The impact of Haemophilus influenzae type b meningitis on nutritional status. American Journal of Clinical Nutrition. 50(3). 425–434. 1 indexed citations
15.
Smith, Arnold L., Bonnie W. Ramsey, Judy Williams‐Warren, et al.. (1989). Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatric Pulmonology. 7(4). 265–271. 123 indexed citations
16.
Smith, Arnold L., Gregory J. Redding, Carl F. Doershuk, et al.. (1988). Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. The Journal of Pediatrics. 112(4). 547–554. 126 indexed citations
17.
Koup, Jeffrey R., Judy Williams‐Warren, C.T. Viswanathan, Allan Weber, & Arnold L. Smith. (1986). Pharmacokinetics of Rifampin in Children II. Oral Bioavailability. Therapeutic Drug Monitoring. 8(1). 17–22. 27 indexed citations
18.
Weber, Allan, Daniel W. Lee, Kent E. Opheim, & Arnold L. Smith. (1985). Quantitation of iothalamate in serum and urine by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 337(2). 434–440. 10 indexed citations
19.
Weber, Allan, Arnold L. Smith, & K E Opheim. (1985). Radioenzymatic assays for aminoglycosides with kanamycin 6'-acetyltransferase. Journal of Clinical Microbiology. 21(3). 419–424. 9 indexed citations
20.
Weber, Allan, Donald O. Chaffin, Arnold L. Smith, & K E Opheim. (1985). Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography. Antimicrobial Agents and Chemotherapy. 27(4). 531–534. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul O. Madsen Breakdown of academic impact, for papers by P Periti Breakdown of academic impact, for papers by Paul M. Beringer Breakdown of academic impact, for papers by Olivier Petitjean Breakdown of academic impact, for papers by Stuart M. Harding Breakdown of academic impact, for papers by F. Sörgel Breakdown of academic impact, for papers by Joost Wauters Breakdown of academic impact, for papers by F. P. V. Maesen Breakdown of academic impact, for papers by Nicolas Grégoire Breakdown of academic impact, for papers by C Grassi
Rankless by CCL
2026